Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.
Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, Reader V, Sweetman G, Bauer A, Bouwmeester T, Hopf C, Kruse U, Neubauer G, Ramsden N, Rick J, Kuster B, Drewes G.
Bantscheff M, et al. Among authors: kuster b.
Nat Biotechnol. 2007 Sep;25(9):1035-44. doi: 10.1038/nbt1328. Epub 2007 Aug 26.
Nat Biotechnol. 2007.
PMID: 17721511